SOLID TUMOR, ADULT

This is the first human study testing the safety and early effects of an experimental drug called BL-M17D1 in people with advanced cancers that have a specific marker called HER2. The trial will enroll 120 adults with various hard-to-treat cancers, including breast, lung, and sto…

This trial is testing whether a new proton beam therapy system called PROTEUS® PLUS is safe and effective for treating various solid tumors in adults. The study will follow 47 patients for up to five years to see how well the treatment controls their cancer and monitor for side e…

This is the first human study of an experimental oral drug called 3D185 for adults with advanced solid tumors that have stopped responding to standard treatments. The main goal is to find a safe dose and see how the body processes the drug in a small group of 42 participants. Res…

This study is testing an investigational drug called TYRA300 for people with advanced bladder cancer and other solid tumors that have specific changes in a gene called FGFR3. The main goals are to find a safe and effective dose and to see if the drug can shrink or control the tum…

This study is testing an experimental drug called HER3-DXd for patients whose cancer has spread to the brain or the lining of the spinal cord. It is for adults with advanced breast cancer, non-small cell lung cancer, or other solid tumors who have already tried at least one other…

This trial is testing a new drug called CTL-002 (visugromab) for adults with advanced solid tumors that have returned or stopped responding to standard treatments, including immunotherapy. The study has two parts: first finding a safe dose, then testing that dose in combination w…

This study is testing a new genetic vaccine, called Nous-209, given alongside the immunotherapy drug pembrolizumab (Keytruda®). The goal is to see if this combination is safe and can help control advanced cancers that have a specific genetic feature (MSI-H or dMMR), including col…

This early-stage study is testing a new oral drug called KIN-2787 in adults with advanced solid tumors that have specific BRAF or NRAS gene mutations, including lung cancer and melanoma. The main goals are to find a safe dose, see how the body processes the drug, and get an early…

This early-stage study is testing a new drug, ICT01, in people with advanced cancers that have come back or stopped responding to other treatments. Researchers want to see if ICT01 is safe, both on its own and when combined with an existing immunotherapy drug (Keytruda). They wil…

This study is testing a new proton beam therapy system called PROTEUS® PLUS to see if it is safe and effective for treating solid tumors in adults. It will enroll 47 participants with various tumors to measure how well the treatment controls the disease and monitor side effects. …

This early-stage study is testing a new drug called AXN-2510 in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find the safest dose, understand side effects, and see how long the drug stays in the body. Participants re…

This early-stage trial is testing a personalized cancer vaccine made from a patient's own immune cells. The cells are engineered to target two specific markers found on some advanced solid tumors. The vaccine is given alongside standard immunotherapy drugs to see if it's safe and…

This study is testing a new proton beam therapy system called PROTEUS® PLUS to see how safe and effective it is for treating solid tumors in adults. The trial will follow 47 patients for 90 days after treatment to measure tumor control and side effects, with additional monitoring…

This early-stage study is testing a new immunotherapy drug called DECOY20, both alone and combined with another cancer drug (tislelizumab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find safe doses, check for s…

This study aims to see if doctors can reliably measure the amount of a common chemotherapy drug (paclitaxel) in a patient's blood. The goal is to learn if tracking these levels can help find the right dose to fight cancer while reducing a severe side effect: nerve damage that cau…

This study tracks the long-term safety of experimental cancer treatments in patients who previously participated in earlier Janssen trials. It follows 80 people with various cancers to monitor for serious side effects over time. The goal is to better understand the safety profile…